ABSTRACT
Introduction
Lung cancer is one of the most common malignancies in human pathology and is a leading cause for death among men. For example during 2006 in Bulgaria the diagnosed new cases with lung cancer were 3600, and accounting for 18.4 % out of all cases among men diagnosed as neoplasms during that year, and for 3.9 % among women (4) . Moreover, a significant problem is the observed increase of the disease rate through the years, being 135.9 new cases per 100 000 people in 2006 and reaching 158.3 in 2008 (3, 4) . During 2006 more than 2700 patients died from lung cancer and the overall mortality among the general population was 43.3 per 100 000 people (74.4 for men and 14.1 for women) (3, 4) .
Lung cancer is a multifactorial disease and among the major factors that contribute for its development are tobacco consumption, factors from the work environment (asbestos, nickel, arsenic, chromium, coal dust, uranium, radon, etc.), air pollution (petrol vapor, aromatic amines, smokes with domestic and industrial origin), chronic pulmonary diseases, and genetic predisposition (17) .
The pathogenesis of the disease includes exposition to cancerogenic substances, which might induce changes in the bronchial mucosa, metaplasia of the cylindrical epithelium into squamous epithelium, followed by dysplastic changes and development of lung cancer after a latent period that may vary in its length. According to the histological examination lung cancer may be divided into four major types: 1. Squamous-cell carcinoma; 2. Adenocarcinoma; 3. Large cell carcinoma; and 4. Small-cell carcinoma (17) .
A commonly used division in the clinical practice of the different types of lung cancer includes: a) non-small cell lung cancer (NSCLC), which groups the squamous-cell, the large cell and the adenocarcinoma; and b) small cell lung cancer, which shows worst prognosis.
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Novel knowledge that concerns the exact underlying mechanisms was gained during the last years. It has been established that the receptor for the epidermal growth factor (EGFR) plays a substantial role on a molecular level in the regulation of important tumorigenic processes such as proliferation, inhibition of apoptosis, angiogenesis, and invasiveness (8, 15, 17) . It has been determined that EGFR together with its specific ligands is commonly overexpressed during the development and progression of NSCLC (Fig. 1) . Research concerning the mutations in the EGFR gene presented data on their role in the pathogenesis of the disease, the estimated prognosis and response rate to a particular therapeutic strategy (14, 17, 19) . (8) EGFR, also known in humans as HER1 or erb-В1, is a member of a family of transmembrane glycoprotein receptors. EGFR is situated on the cell surface and is structured by an extracellular ligand-binding domain, a transmembrane and a cytoplasmic domain with a tyrosine kinase activity (6) . When associated with a specific ligand, EGFR forms homoor hetero-dimers which activates the internal tyrosine kinase activity and the subsequent signaling cascades. These mainly include the Ras-Raf-MAP kinase, PI3K-Akt and STAT signaling pathways. They all exhibit a strong stimulatory effect on tumor cells in terms of their proliferation, differentiation, survival rate, angiogenesis, migration and adhesion. EGFR is overexpressed in as much as 80 % of the NSCLC cases, which is associated with worse prognosis (6, 14, 17) . Such high rate makes the disease a major health problem that determines high morbidity and mortality rates.
The scientific advance on the molecular level allows the development of novel biotechnology based medicines. Recently, an EGFR inhibitor was developed and introduced in the clinical practice (6) . The drug gefitinib, registered also in Bulgaria under the trade name IRESSA ® , is applied as a new alternative approach to the treatment of certain breast, lung and other cancers (18) . Gefitinib interrupts the excessive growth signaling in the targeted cells, as it selectively binds and blocks the tyrosine kinase domain of the EGFR (Fig. 1) . A general condition in order for the drug to be effective is the presence of a mutated and overactive EGFR.
However, in order to determine the effectiveness in terms of benefits for the budgetary expenses, an objective and through pharmacoeconomical analysis is needed.
This study aims to make a time-updated model analysis of the cost-of-therapy and to evaluate the impact on the health budget for this particular novel biotechnology based therapy, if it is routinely introduced as an alternative strategy for treatment. The analysis covered the treatment of patients with a mutation in the EGFR gene (EGFR M+) with a non-small cell lung cancer in stage IIIB/IV, where gefitinib was employed as a first line therapy. The study takes into account the latest research from the published scientific literature, expert-and local-specific data from the Bulgarian health system.
Materials and Methods
Study population
Patients diagnosed with an advanced non-small-cell lung cancer at stage IIIB/IV were investigated. Inclusion criteria were set to previously chemotherapy naive patients, which were diagnosed with an advanced NSCLC in stage ІІІB/ІV and harbor mutation in the gene for the EGFR (EGFR M+).
Study design
The investigation was conducted from the perspective of the payer (the healthcare insurance companies). The analysis included direct medical costs, including acquisition expenses for medicines, the costs for administering the corresponding therapies, costs for treatment of adverse events, costs of supportive therapy and expenses related to the care of patients that directly increase the budget of compulsory healthcare insurance.
Pharmacoeconomical methods
The analysis used Costs-of-therapy methods in order to evaluate the routine application of several therapeutic approaches as a first treatment option for EGFR M+ patients with NSCLC in stage ІІІB/ІV.
The costs for the therapy are considered as direct medical costs. They are usually associated with monetary transactions and are incurred during the provision of care such as payments for purchasing a medicinal product, physicians' payments, diagnostic tests, etc. Because charges might not accurately reflect the consumed resources a pharmacoeconomic technique is used to determine the direct costs for the therapy. Cost-oftherapy studies can help resources to be used more effectively and more extensive cost-benefit analyses could be made between alternative courses. Finally not the actual amount of money but the economic advantages should be a deciding factor. 
Gefitinib -250 mg/daily Until a progression is observed
The gefitinib therapy is initiated after preliminary genetic analysis. The test evaluates if mutations in exon 19 and/or exon 21 of the EGFR gene are present. It should also be noted that gefitinib is distributed in a solid dosage form -film-coated tablet, which shows certain benefits (18, 19) .
The budgetary impact analysis (BIA) allows a precise evaluation of: the necessary resources in order for a particular therapeutic protocol to be made available; the differences in terms of costs between different treatment approaches; financial outcome when novel strategies and medications are applied.
The prices of medications and health services that were taken for the purpose of the study were expressed in the Bulgarian currency (lev, BGN) with a reference exchange rate of 1.95583 BGN for 1 Euro. A VAT equal to 20 %, established currently in Bulgaria was considered.
Results and Discussion
According to the Bulgarian National Guidelines (2) for systemic therapy of solid malignancies an indication for the use of chemotherapy is a disease classified as a clinical stage IIIB or IV. The first therapeutic line includes 4-6 courses and in the case of EGFR M+ NSCLC the chemotherapy consists mainly of one of the four described protocols.
Therapeutic efficiency
The therapeutic efficiency of particular medicines or combinations of drugs that were included in the study was determined according to scientific publications that reflect major clinical trials (9, 12, 13, 14, 15, 16, 18, 21) . The routine clinical practice in Bulgaria involves the combination of Cisplatin and Gemcitabine (2) . An alternative approach in EGFR M+ patients is the application of IRESSA ® . According to data from an investigation of 288 patients, out of which 86 % being in a clinical stage ІV, the average survival rate after the routine Cisplatin + Gemcitabine therapy was 8.1 months (13) . Phase III of the INTEREST study showed that after therapy with gefitinib in patients with NSCLC different from an adenocarcinoma the average survival rate was 6.4 months (12) . Additional therapeutic strategies include the application of combinations between Cisplatin, Gemcitabine and Bevacizumab or between Cisplatin and Pemetrexed. Again IRESSA ® is available as an alternative strategy. According to a clinical trial involving 847 patients the average survival rate after therapy with Cisplatin combined with Pemetrexed was 12.6 months (21). The AVAiL study determined that after the application of the combination Cisplatin + Gemcitabine + Bevacizumab the average survival rate was 13.6 months and the average progression free period was 6.8 months (16) . The IPASS clinical trial determined that after a therapy with IRESSA ® , the average survival time was 18.6 months, and the average progression free time was 5.7 months in the general group of participants and 9.5 months for the EGFR M+ patients (18) . The IPASS study presented valuable information on the objective response rate in patients undergoing a therapy with IRESSA ® . It was compared to the combination carboplatin/paclitaxel with a rate of 47.3 %, and for IRESSA ® it was established as 71.2 %.
Therapeutic expenses
The pharmacoeconomical analysis was performed from the perspective of the healthcare insurance institutions. Thus the following direct medical expenses were considered, which were directly associated with the budget of the compulsory healthcare insurance (5, 20):
• gefitinib purchase expences;
• purchase expenses for alternative anticancer medications that are currently applied; • expenses associated with vomit prevention; • healthcare costs; • expenses associated with adverse reactions treatment.
Gefitinib purchase expences
The recommended daily dose for the medicine gefitinib (IRESSA ® ) is 250 mg and the therapy is continued as long as clinical benefit is achieved or adverse drug reactions are not overly expressed. A calculation model with 60 days for treatment response and overall course of 114 days (3.8 months) was accepted, although large randomized studies showed that in EGFR M+ patients longer progression free intervals are achieved when IRESSA ® is applied as a first line therapy. This calculation model was approved for better comparability to alternative therapeutic courses.
Prices were determined by the Bulgarian Drug Price and Reimbursement Commission according to the local legislation and after the reference pricing system was applied as of October 2010. Table 1 presents details for the medication gefitinib and shows data for the wholesale purchase price of IRESSA ® valid for Bulgaria and the daily expenses for the therapy.
The expenses for gefitinib are calculated according to the wholesale value without VAT and do not include the pharmaceutical expenses for supply, storage and distribution. Purchase expenses for alternative anticancer medications Other therapeutic options are available as a first line of therapy for NSCLC. In order to calculate these purchase costs, the most inexpensive generic equivalent to certain anticancer medications was chosen. It was accepted that for one course the solution of the anticancer medication is prepared with the minimal possible leftover. The prices of a total of 40 anticancer generic equivalents were reviewed and the least expensive ones were selected for the following calculations ( Table 2 ). The exact therapeutic protocols applied for NSCLC with the respective medication prices and calculations for a round/cycle are presented in Table 3 .
In order to compare the different protocols an average of 6 rounds per course were accepted in the time frame of approximately 4 months if a therapeutic response was present. This study did not review a scenario with a second line of therapy when therapeutic response is not achieved after the second month. The overall duration of the chemotherapeutic courses did not exceeded 6 months, where during this period 4 to 6 courses were recommended.
Expenses associated with vomit prevention
Anticancer drugs exhibit emetogenic potential that may vary in its type and intensity (1, 10, 23). There are acute, subsequent and anticipative nausea and vomiting. Different types of antiemetic drugs are applied before, during or after chemotherapy in relation to characteristics of each particular anticancer medication. The smallest medication unit for parenteral usage that was considered in the calculations was accepted to be an ampoule. Costs associated with pharmaceutical expenses were not included due to lack of established country applicable inclusive rates.
The selected anticancer drugs are classified according to their emetogenic potential and data is presented in Table 4 together with the appropriate approach for vomit prevention (1, 10, 22, 23) . The respective antiemetic medications used for the different anticancer schemes with their costs are presented in Table 5 .
Healthcare costs
Anticancer treatment is associated with regular examination from medical specialists, with laboratory tests and expenses concerning the preparation and application of the respective medications. The price list of the different health care procedures, manipulations and exams in the University Hospital "Tsaritsa Yoanna -ISUL" (http://isul.eu/za_pac_ ceni.htm as viewed in August 2010) was selected as a basis in order to calculate the direct health care expenses of an insured patient.
When oral intake of anticancer drugs was administered the pharmacoecomic analysis considered an average cost of 50 BGN, which included examination of a single patient (30 BGN) and routine laboratory tests (20 BGN) . In the scenario when cytostatic medications for parenteral application were administered, the overall cost for examination, preparation and application of the medications, laboratory tests and medical personnel was established at 1500 BGN per therapeutic course. The oral intake of drugs necessitated a reexamination every second month if the disease did not advance, while for the parenteral cytostatic treatment exams were needed at least twice per month or according to the cycles of the therapeutic course.
When the direct costs for application of each therapy were calculated, the expenses concerning the transport of oncology patients for examination at the hospital sites were not considered. The healthcare insurance system in Bulgaria does not allow family transport costs to be covered. Another important issue from a pharmacoeconomical point of view is the significant portion of indirect expenses concerning the health care of the patients, including economic losses in relation to work absence and the immediate decrease in the net income of the household. Due to lack of standardized values and commonly accepted methodology for calculation of these expenses in Bulgaria, the study was limited to evaluation of indirect therapeutic costs associated with adverse reactions.
Indirect expenses associated with adverse reactions
The results of the IPASS clinical trial served as a basis for the prevalence of adverse reactions to be determined when gefitinib or the combination paclitaxel/carboplatin was applied (18) . Summarized data is presented in Table 6 . The prevalence of adverse reactions for the alternative therapeutic strategies was applied according to the meta-analysis of Eduards et al. (7) . This investigation presented the adverse reaction in comparison to the combination paclitaxel/carboplatin. Data concerning this combined therapy was also applied when a particular prevalence was not indicated for a given alternative therapy.
The expenses related to management of major adverse reactions for the current analysis included the following:
• expenses associated with acute anemia;
• expenses associated with diarrhea;
• expenses associated with febrile neutropenia;
• expenses associated with supportive care and dyspnoea. It was assumed that healthcare assistance is only necessary when grade 3 and 4 adverse reaction is present according to the Commom Toxicity Criteria (CTC). A single package was accepted as the smallest possible unit for the outpatient medications used in the calculations. For all other drugs that are applied during the hospital admittances the smallest unit was defined as tablet and capsule or ampule in the case of parenteral medications.
Expenses associated with acute anemia
Most patients with a hemoglobin rate below 90 g/l, or patients showing symptoms associated with anemia such as fatigue, weakness, shortness of breath, palpitations etc., need transfusion of concentrated erythrocytes. Patients with onset of acute anemia are subjected to an average of 3 units of concentrated erythrocytes during the course of anticancer therapy (20) . Blood unit transfusion is applied in a day-care facility. Costs associated with the therapy of anemia grade 3 or 4 are summarized in Table 7 . Approximately 10 % to 20% of patients with anemia are given erythropoetin during their therapy. This pharmacoeconomic study considered an average of 15 % from the patients to be given Eprex ® 10 000 IU three times per week. As dosage is personalized and the duration of the course depends on the achieved hemoglobin rates, a medium course of 8 weeks is accepted ( Table 7) .
Expenses associated with diarrhea
The onset of diarrhea is managed by most patients in ambulatory settings (23) . A common prescription for this scenario includes loperamide, which then is not covered by the healthcare insurance fund. If a grade 3 or 4 diarrheal syndrome is present (5 % of all patients), hospitalization is needed with rehydration therapy and loperamide. An average stay of 3 days with loperamide twice daily and two units of 1000 ml saline were considered ( Table 7) .
Expenses associated with febrile neutropenia
Febrile neutropenia necessitates empirical treatment in hospital with ciprofloxacin or amoxicillin/clavulanic acid. The therapy usually lasts 8 days. The costs for the antibiotic of choice are presented in Table 7 (2, 23).
Expenses associated with supportive pharmacotherapy
and dyspnoea Supportive pharmacotherapy consists in pain management, dyspnoea prevention or measures intended to preserve and improve lung functions (2, 11, 23) .
Most lung cancer patients experience more or less pronounced pain either due to the primary lung disease or as a result of metastases elsewhere in the body (for example bone metastasis). The disease is treated according to the principles of WHO (11) . ESMO directives bring evidence that at least 80 % of patients with advanced cancer disease are in pain, which is mainly related to tumor growth in the surrounding soft tissues. The effects of surgical, radio-and chemotherapy are causes for the remaining 20 % of the pain cases. Somatic pain is treated in a similar manner to neuropathic pain. The latter occurs after surgery in 10 % to 15 % of patients and may also be caused by tumor ingrowth into the bronchial nerve plexuses.
Dyspnoea is observed in 60 % of all patients and is associated with coughing and copious expectoration (bronchorrhea). Mydazolam is usually applied in order to cope with the symptoms.
Costs for supportive pharmacotherapy are presented in Table 7 .
Overall expense analysis
The implementation of cost-benefit analysis (Table 8) showed that gefitinib should be the medication of choice for the treatment of non-small cell lung cancer. This is warranted by the significant difference in both the survival period and costs of therapy when compared to alternative therapeutic strategies. This model pharmacoeconomic study clearly reveals a beneficial association between a novel biotechnological approach and the benefit for both the payer (the healthcare insurance companies) and the patient.
Overall impact on the Healthcare Insurance Budget
Considering the positive cost-effectiveness ratio when gefitinib is applied in the therapy of non-small cell lung cancer, an analysis on the budget impact may be developed. The calculations show that the application of the medication in as little as 10 patients per year may lead to savings of nearly 31 000 BGN/15 850 Euro, equal to 16 % of the expenses needed for alternative therapeutic approaches ( Table 9 ). in the long term and considering the increasing number of patients in a five-year period the potential savings may be increased to 20 %.
Conclusions
Novel biotechnological research allows the development of new therapeutic molecules. However their application in the routine clinical practice requires validation in terms of mechanism and efficiency and last but not least, the economic appropriateness of routine clinical application. This pharmacoeconomic study analyzed the impact of therapy with gefitinib, a state-of-the-art novel biotechnological medicine, through comparison with commonly used alternatives. The analysis showed:
1. A significantly higher progression free survival rate when gefitinib was applied for therapy of non-small cell lung cancer in EGFR mutation positive patients, in comparison with chemotherapy; 2. A positive cost-effectiveness ratio when gefitinib was used; 3. A potential for possible costs savings equal to an annual average of approximately 16 %, in comparison to the routinely used conventional therapy; 4. A relatively lower risk for adverse reactions grade 3 or 4 and a significant decrease of indirect costs related to their management; 5. Improved patient compliance, that leads to decreased direct non-medical costs related to application of the IRESSA ® therapy.
